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A four-step preparation of compounds containing a pyrimidine moiety is presented. This synthesis involves especially a 
Vilsmeier–Haack reaction and the synthesized compounds screened for their antibacterial activity against Gram-positive and 
Gram-negative organisms, as well as for antifungal activities. Structures of all the newly synthesized compounds were 
confirmed by their FTIR, 1H NMR, mass spectral and elemental analysis data. Some of the newly synthesized compounds 
show excellent antimicrobial activity and appear to be the most proficient members of the series. 
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The treat for convenient microbial infections has 
become essential and demanding due to the urgent 
multiplication of multiple drug-resistant organisms1,2. 
Antimicrobial resistant (AMR) is a phenomenon of 
infectious microbial flora to resist antimicrobial agents 
to which it was previously sensitive3. Thus, there is a 
vital need to improve drug resistance by finding more 
useful pharmacological agents. In addition Nitrogen 
sulphur and oxygen containing heterocycles are of 
significant interest for designing various chemical 
substances that may serve as lead for discovering novel 
bioactive agents. 
The diversity in the biological response of  
4-thiazolidinones has attracted the attention of many 
researchers to explore this framework for its potential. 
It is, therefore, of prime importance that the study of 
this topic and the development of new synthetic 
strategies should be based on the most recent 
knowledge, emerging from the latest research4. 
Moreover, thiazolidin-4-one derivatives are also 
reported to have important biological activities such as 
anti-inflammatory5, anti-tuberculosis6, anti-cancer7, 
anti-tumor8, anti-HIV9, anti-bacterial10, anti-fungal11, 
anti-oxidant12, anti-viral13, anti-convulsant14, 
diuretics15, nematicidal16, anti-histaminic17 activity, etc. 
The presence of heterocycles in all kinds of organic 
compounds applied in biology, pharmacology, optics, 
electronics, material sciences, and so on is very well 
known. Between them, oxygen, sulfur and nitrogen-
containing heterocyclic compounds have maintained 
the interest of researchers due to their biological 
activities and unique structures that led to several 
applications in different areas of agrochemical and 
pharmaceutical research as well18. 
To alleviate the multi drug resistance dilemma, 
nitrogen, sulfur and oxygen based compounds 
appeared with promising therapeutic agents. These 
include various pyrimidine, Schiff base, and 4-
thiazolidinone moieties which appears with good 
biological potential. 
 
Results and Discussion 
 
Chemistry 
The strategy acquired for the synthesis of 7a-d, 8a-d 
and 9a-d is depicted in Scheme I. The attack of sulphur 
nucleophile on imine carbon followed by 
intramolecular cyclization with elimination of water 
gives 2, 3-disubstituted-4-thiazolidinones (8a-d) and 
2,3-disubstituted-5-methyl-4-thiazolidinones (9a-d) 
derivatives which were confirmed by spectral analysis. 
The formation of the compounds was confirmed by 
their FT-IR, 1H NMR, mass spectra as well as 
elemental analysis. As an example, in the IR spectrum 
of compound 7c, characteristic is the N=CH stretching 
vibration, which appear as an intense band at 1622 cm-
1
. There was no absorption in between 3300-3400 cm-1 
which confirmed that free amino group of thiazole ring 
is converted into a proposed imine. The structural 
element characteristic for the thiazole nucleus, namely; 
the stretching vibration band for the C=N, C-S-C 
linkage and CH3 stretching were observed at 1545, 679 
and 1382 cm-1 respectively. In morpholine ring the 
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stretching vibration band for the C-N and C-O-C 
linkage was observed at 1369 and 1130 cm-1. Several 
bands appeared at 1476 and 3073 cm-1 are due to the 
stretching of C=C and C-H vibrations of aromatic ring 
and the stretching vibration band for OCH3 group is 
observed at 1183 cm-1 respectively. The 1H NMR 
spectrum of compound 7a-d did not only show the 
absence of NH2 protons of amine unit as singlet signal 
at between δ 5-6 ppm but exerted a singlet at higher 
field at δ 8.6 ppm for -CH=N proton of the imine 
group. Moreover the compound 7c showed emphasized 
signal as singlet for the methyl group protons of 
thiazole core at δ 2.56 ppm. The two singlet of 
methoxy group protons are observed at δ 3.68 and 3.77 
ppm. 
The strong absorption band observed at 1650 -1750 
cm-1for the presence of C=O group and 600 -700 cm-1 
for the presence of C-S-C linkage of thiazolidine unit 
in both 8a-d and 9a-d. There was no absorption in the 
region of 1605-1621 cm-1 which signifying the 
disappearance of imine group in this structure. 
Moreover the compound 9a showed a strong 
absorption band at 1350 cm-1 due to the presence of the 
CH3 group attached on the C-5 position of thiazolidine 
ring which also confirmed the cyclo-condensation of 
imine. A broad stretching band for the C=N 
functionality and OCH3 group of pyrimidine ring is 
observed at between 1495-1635 cm-1 and 1100-1200 
cm-1 respectively. The 1H NMR spectrum of compound 
8d showed two doublet of doublet at δ 3.6 (J = 4.8 Hz) 
and 3.9 ppm (J = 4.6 Hz) due to CHX and CHy protons 
of active methylene group of the thiazolidine ring. The 
1H NMR spectrum of compound 9a showed diagnostic 
peaks at δ 5.8 and 4.0 ppm (J = 7.3 Hz) as singlet and 
quartet due to Ar-CH and CH-CH3 proton of the 
thiazolidine ring system. The disappearance of the 
N=CH proton at between δ 8-9 ppm as singlet also 
supported presence of thiazolidine ring in compound 8e 
and 9a. The other remaining aromatic protons appeared 
as a multiplet signal at between δ 6.8-7.8 ppm along 
 
 
Scheme I — Methodical synthetic route for the target compounds 7a-e, 8a-e and 9a-e 
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with singlet in between δ 3.5-3.9 ppm corresponding to 
the methoxy group protons. Finally, mass spectra of all 
the title compounds showed molecular ion peak M+ 
corresponding to their mass which is also in agreement 
with its proposed structure. The obtained elemental 
analysis values are in good agreement with theoretical 
data. 
 
In vitro antimicrobial activity 
In vitro antibacterial and antifungal activity of 
newly synthesized compounds (7a-d), (8a-d) and 
(9a-d) was carried out by micro broth dilution method 
according to National Committee for Clinical 
Laboratory Standards (NCCLS, 2002)19. A panel of 
selected pathogens Gram positive (Staphylococcus 
aureus MTCC 96 and Bacillus cereus MTCC 430) 
and Gram negative (Escherichia coli MTCC 443 and 
Klebsiella pneumonia MTCC 109) bacterial species 
used for antibacterial activity whereas for antifungal 
activity, a panel of selected fungal pathogens 
(Candida albicans MTCC 227, Aspergillus niger 
MTCC 282 and Aspergillus calavatus MTCC 1323) 
species were used. 2% DMSO solution was used as 
diluent to get desired concentration of drugs to test 
upon standard bacterial and fungal strains. The zone 
of inhibition produced by each compound was 
measured in µg/ml. The minimum inhibitory 
concentration (MIC) was determined and recorded at 
the lowest concentration inhibiting growth of the 
organism. Ciprofloxacin were used as standard 
antibiotic drugs for antibacterial activity while 
Ketoconazole were used as standard drug for 
antifungal activity (Table I). 
 
Experimental Section 
All the chemicals and solvents used for the 
synthesis work acquired from commercial sources 
were of analytical reagent (AR) grade. Melting points 
were determined by using open capillary tubes and 
are uncorrected. TLC was checked on E-Merck pre-
coated 60 F254 plates and the spots were rendered 
visible by exposing to UV light or keeping the plates 
in iodine chamber. IR spectra were recorded on a 
Shimadzu FTIR 8401 spectrophotometer using 
potassium bromide pellets. 1H NMR were recorded on 
a Bruker Avance 400 MHz spectrometer (Bruker 
Scientific Corporation Ltd., Switzerland) using 
DMSO as a solvent and TMS as an internal standard 
at 400 MHz. Chemical shifts are reported in parts per 
million (ppm). The following abbreviations have been 
used to explain the observed multiplicities: s, singlet; 
d, doublet; dd, double doublet; t, triplet; m, multiplet. 
Elemental analyses were carried out by Perkin-Elmer 
2400 series-II elemental analyser (Perkin-Elmer, 
USA).  
 
Preparation of N-(2, 6-dimethoxypyrimidin-4-yl) 
acetamide, 2 
(0.01 mole) of compound (1) (10 mL) of Acetic 
anhydride and 1-2 drops of acetic acid was added and 
the mixture was heated under reflux for 6 h. The 
reaction mixture was poured into crushed ice (200 g) 
with stirring. The progress of reaction was monitored 
Table I — Antimicrobial activity of the synthesised compounds 
Compd Minimal bactericidal concentration µg/mL Minimal fungicidal concentration µg/mL 
Gram positive  Gram negative 
S. a MTCC-96 S. p MTCC-442 E. c MTCC-443 K. p MTCC-441  C. a MTCC-227 A. n MTCC-282 A. c MTCC-1323 
7a 50 50 200 3.125 100 100 100 
7b 12.5 50 6.25 12.5 100 100 100 
7c 100 100 200 12.5 50 50 100 
7d 12.6 12.5 3.125 100 50 100 50 
8a 100 50 12.5 100 100 50 50 
8b 6.25 100 3.125 50 50 100 50 
8c 100 100 100 100 100 50 100 
8d 12.5 50 3.125 50 50 100 50 
9a 100 6.25 12.5 25 50 25 50 
9b 6.25 12.5 25 50 25 50 50 
9c 12.5 6.25 12.5 25 50 50 25 
9d 100 100 6.25 12.5 100 100 50 
A 3.125 3.125 3.125 3.125 – – – 
B – – – – 3.125 3.125 3.125 
A=Ciprofloxacin, (Standard Drugs for antibacterial activity) B = Ketoconazole (Standard Drugs for antifungal activity). 
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by TLC using ethyl acetate: hexane (6:4) as eluent. 
The solid product obtained was filtered, washed with 
water and dried. The crude product was purified  
by crystallization from acetone to get the title 
compound (2). 
 
Preparation of 7-Chloro-2, 4 –dimethoxy 
pyrido[2,3-d]pyrimidin-6-carbaldehyde, 3 
A mixture of compound (2) (0.810 mg, 5 m mol) in 
DMF (4.0 mL, 50 m mol), POCl3 (0.5 ml, 5 m mol) 
was added at room temperature, producing a semi-
solid mass. A clear solution appeared after stirring for 
4 h at room temperature. It was further stirred for 6 h. 
The reaction mixture was poured into crushed ice 
(200 g) with stirring. The separated solid was filtered 
off and washed thoroughly with water. The progress 
of reaction was monitored by TLC using ethyl 
acetate: hexane (6:4) as eluent. The solid product 
obtained was filtered, washed with water and dried. 
The crude product was purified by crystallization 
from acetone to get the title compound (3). 
 
Preparation of 2, 4 – dimethoxy-7-morpholino 
pyrido[2, 3-d]pyrimidine-6-carbaldehyde, 5 
A solution of morpholine (4) (1.75 g, 20 m mol) in 
10 ml of dichloromethane was gradually added under 
stirring to an ice-cooled mixture of compound (3). 
After stirring for 30 min. at 0-5°C the mixture was 
washed with 3 x 10 ml of water in order to remove 
unreacted morpholine and its salt. The organic phase 
was dried over MgSO4 and the solvent was 
evaporated under reduced pressure. The dry, flake-
like residue were recrystallized from 1, 4-dioxane. 
The progress of reaction was monitored by TLC using 
chloroform: methanol (9:1) as eluent. The crude 
product was purified by crystallization from acetone 
to get the title compound (5). 
 
General Preparation of substituted Schiff bases, 
7a-e 
A solution of (4) (2.0 g, 20 m mol) in 20 ml ethanol 
was added to equimolecular quantities of an amine (6) 
add 1-2 drop of acetic acid. The reaction mixture was 
refluxed for 3 h at 60-70ºC, separated solid was 
filtered off and washed thoroughly with water. The 
progress of reaction was monitored by TLC using 
ethyl acetate: hexane (6:4) as eluent. The solid 
product obtained was filtered, washed with water  
and dried. The crude product was purified  
by crystallization from acetone to get the title 
compound (7).  
General preparation of 2, 3-disubstituted-4-
thiazolidinone, 8a-e 
A mixture of substituted substituted Schiff base (7) 
(3.56 g, 1 mol), DMF (50 ml), pinch of Zncl2 and 
thioglycolic acid (1.84 g, 2 mol) was refluxed for 12 - 
15 hours. Excess solvent was distilled off under 
reduced pressure. Progress of reaction was monitored 
by TLC using ethyl acetate: hexane (4:6). After the 
completion of reaction it was cooled and the product 
was filtered, washed with dilute sodium bicarbonate 
solution to remove unreacted acid and dried over 
anhydrous Na2SO4 to get substituted 4-thiazolidinone 
derivatives. 
 
General preparation of 2, 3-disubstituted-5-
methyl-4-thiazolidinone, 9a-e 
A mixture of substituted Schiff- base (7) (3.56 g, 1 
mol), DMF (50 mL), Zncl2 and thiolacticacid (1.84 g, 
2 mol) was refluxed for 12-15 hours. Excess solvent 
was distilled off under reduced pressure. Progress of 
the reaction was monitored by TLC using ethyl 
acetate: hexane (4:6). After the completion of the 
reaction it was cooled and the product was filtered, 
washed with dilute sodium bicarbonate solution to 
remove unreacted acid and dried over anhydrous 
Na2SO4 to get substituted 4-thiazolidinones 
derivatives. 
All the synthesised compounds (7a-d), (8a-d) and 
(9a-d) were characterised by IR, 1H NMR, and MS as 
well as elemental analysis. The characteristic data of 
the entire synthesised compounds are given in the 
spectral analysis data. 
 
Specrtal and analytical analysis data 
N-(2, 6-dimethoxypyrimidin-4-yl) acetamide, 2: 
White solid, m.p: 107-110oC; Yield: 82%; IR (KBr, 
Vmax/cm-1): 3076 (C-H str., aromatic), 1593 (C=C 
str., aromatic), 1591 (C=N str., pyrimidine ring ), 
1370 (CH3 str.), 1681 (C=O str.), 3179 (-NH str. 
2ºamine), 1177 (-OCH3 str.); 1H NMR (400 MHz, 
DMSO-d6, δ ppm): 9.52 (s, 1H, 2ºamide), 2.54 (s, 3H, 
CH3), 3.64 (s, 3H,OCH3), 3.73 (s, 3H, OCH3), 8.31 (s, 
1H, Ar-H); MS m/z 198.08 (M+ +1) Anal. Calcd. For 
C8H11N3O3: C, 48.73; H, 5.62; N, 21.31%. Found C, 
48.76; H, 5.65; N, 21.35%. 
7-Chloro-2,4-dimethoxypyrido[2,3-d]pyrimidine-
6-carbaldehyde, 3: Light-yellow, m.p: 115-120oC; 
Yield: 77%; IR (KBr, Vmax/cm-1): 3076 (C-H str., 
aromatic), 1593 (C=C str., aromatic), 1591 (C=N str.), 
1681 (C=O str. aldehyde), 2785-2845 (C-H str. 
Aldehyde), 709 (C-Cl str.), 1177 (-OCH3 str.); 1H 
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NMR (400 MHz, DMSO-d6, δ ppm): 9.52 (s, 1H, -
CHO), 3.61 (s, 3H, OCH3), 3.71 (s, 3H, OCH3), 8.33 
(s, 1H, Ar-H); MS m/z 254.2 (M+ +1) Anal. Calcd. 
For C10H8ClN3O: C, 47.35; H, 3.18; N, 16.57 %. 
Found C, 47.32; H, 3.15; N, 16.54%. 
2,4-Dimethoxy-7-morpholinopyrido[2,3-d]pyr 
imidin-6-carbaldehyde, 5: Light-yellow, m.p: 102-
105oC; Yield: 70; IR (KBr, Vmax/cm-1): 3078 (C-H 
str., aromatic), 1598 (C=C str., aromatic), 1590 (C=N 
str. ), 1681 (C=O str. aldehyde), 2785 – 2845 (C-H 
str. Aldehyde) 1136 (C-O-C str., morpholine ring), 
1374 (C-N str., morpholine ring); 1H NMR (400 
MHz, DMSO-d6, δ ppm): 9.52 (s, 1H, -CHO), 3.62  
(s, 3H, OCH3), 3.71 (s, 3H, OCH3), 8.34 (s, 1H, Ar-
H), 2.36 (t, 4H,CH2 morpholine ring), 2.42 (t, 4H, 
morpholine ring); MS m/z 305.11 (M+ +1) %; Anal. 
Calcd. For C14H16N4O4: C, 55.26; H, 5.30; N, 18.41%. 
Found C, 55.23; H, 5.33; N, 18.44%. 
(E)-N-((2, 4-dimethoxy-7-morpholinopyrido[2,3-
d]pyrimidin-6-yl) methylene) thiazol-2-amine, 7a: 
Orange solid; m.p: 190-194oC; Yield: 72; IR (KBr, 
Vmax/cm-1): 3070 (C-H str., aromatic), 1483 (C=C str., 
aromatic), 1451 (-C=C-C- str., aromatic), 1558 (C=N 
str.), 1547 (C=N str., imine), 1187 (OCH3 str.), 1138 
(C-O-C str., morpholine ring), 1375 (C-N str., 
morpholine ring); 1H NMR (400 MHz, DMSO-d6, δ 
ppm): 2.35 (t, 4H, CH2 , morpholine), 2.42 (t, 4H, CH2, 
morpholine), 3.66 (s, 3H, -OCH3), 3.75 (s, 3H, -OCH3), 
8.55 (s, 1H, CH=N), 7.24 (s, 1H, Ar-H), 7.35 (s, 1H, 
Ar-H), 7.47 (s, 1H, Ar-H); MS m/z 387.5 (M+ +1) %; 
Anal. Calcd. For C17H18N6O3S: C, 52.85; H, 4.70; N, 
21.75%. Found C, 52.82; H, 4.74; N, 21.72%. 
(E)-N-((2, 4-dimethoxy-7-morpholinopyrido[2,3-
d]pyrimidin-6-yl) methylene) -5-methylthiazol-2-
amine, 7b: Orange solid; m.p: 188-191oC; Yield: 70; 
IR (KBr, Vmax/cm-1): 3073 (C-H str., aromatic), 1476 
(C=C str., aromatic), 1467 (-C=C-C- str.,aromatic), 
1558 (C=N str.), 1622 (C=N str., imine), 1183 (OCH3 
str.), 1130 (C-O-C str., morpholine ring), 1369 (C-N 
str., morpholine ring), 1545 (C=N str. thiazole) 679 
(C-S-C linkage, thiazole), 1382 (-CH3 str. thiazole); 
1H NMR (400 MHz, DMSO-d6, δ ppm): 2.38 (t, 4H, 
CH2 , morpholine), 2.40 (t, 4H, CH2,morpholine), 
3.68 (s, 3H,-OCH3), 3.77 (s, 3H,-OCH3), 8.61 (s, 1H, 
CH=N), 7.23 (s, 1H, Ar-H), 2.56 (s, 3H, -CH3), 7.46 
(s, 1H, Ar-H); MS m/z 401.2 (M+ +1) %; Anal. Calcd. 
For C18H20N6O3S: C, 53.99; H, 5.03; N, 20.99%. 
Found C, 53.96; H, 5.07; N, 20.96%. 
(E)-N-((2,4-dimethoxy-7-morpholinopyrido[2,3-
d]pyrimidin-6-yl) methylene) -5-methyl-1, 3, 4-
thiadiazol-2-amine, 7c: Orange solid; m.p: 167-
170oC; Yield: 65%; Anal. Calcd. For C17H19N7O3S: C, 
50.86; H, 4.77; N, 24.42%. Found C, 50.83; H, 4.75; 
N, 24.45%; IR (KBr, Vmax/cm-1): 3088 (C-H str., 
aromatic), 1486 (C=C str., aromatic), 1459 (-C=C-C- 
str.,aromatic), 1565 (C=N str.), 1628 (C=N str., 
imine), 1179 (OCH3 str.), 1143 (C-O-C str., 
morpholine ring), 1377 (C-N str., morpholine ring), 
1366 (-CH3 str.); 1H NMR (400 MHz, DMSO-d6, δ 
ppm): 2.38 (t, 4H, CH2 , morpholine), 2.41 (t, 4H, 
CH2,morpholine), 3.68 (s, 3H,-OCH3), 3.78 (s, 3H,-
OCH3), 8.60 (s, 1H, CH=N), 7.24 (s, 1H, Ar-H), 2.54 
(s, 3H, -CH3) ; MS m/z 402.2 (M+ +1). 
(E)-5-(((2,4-dimethoxy-7-morpholinopyrido[2,3-
d]pyrimidin-6-yl)methylene) amino) -1, 3, 4-
thiadiazol-2-thiol, 7d: Orange solid; m.p: 164-168oC; 
Yield: 68; IR (KBr, Vmax/cm-1): 3072 (C-H str., 
aromatic), 1476 (C=C str., aromatic), 1458 (-C=C-C- 
str.,aromatic), 1554 (C=N str.), 1631 (C=N str., 
imine), 1183 (OCH3 str.), 1137 (C-O-C str., 
morpholine ring), 1367 (C-N str., morpholine ring), 
2575 (-SH str.); 1H NMR (400 MHz, DMSO-d6, δ 
ppm): 2.47 (t, 4H, CH2, morpholine), 2.47 (t, 4H, 
CH2, morpholine), 3.96 (s, 3H, -OCH3), 3.97 (s, 3H, -
OCH3), 7.67 (s, 1H, CH=N), 6.94 (s, 1H, Ar-H), 8.79 
(s, 1H, -SH) ;MS m/z 420.4 (M+ +1) %; Anal. Calcd. 
For C16H17N7O3S2: C, 45.81; H, 4.08; N, 23.37%. 
Found C, 45.85; H, 4.05; N, 23.33%. 
2-(2,4-Dimethoxy-7-morpholinopyrido[2,3-d]pyr 
imidin-6-yl)-3-(thiazol-2-yl) thiazolidin-4-one, 8a: 
Reddish solid; m.p: 175-180oC; Yield: 70; IR (KBr, 
Vmax/cm-1): 3347 (C-H str., aromatic), 2988 (C-H 
str., alkane), 1561 (C=C str., aromatic), 1471 (-C=C-
C- str., aromatic), 1679 (C=O str., thiazolidine), 689 
(C-S-C linkage, thiazolidine ring); 1H NMR (400 
MHz, DMSO-d6, δ ppm): 2.39 (t, 4H, CH2 , 
morpholine), 2.42 (t, 4H, CH2, morpholine), 3.66 (s, 
3H, -OCH3), 3.74 (s, 3H, -OCH3), 6.99 (s, 1H, Ar-H), 
3.95 (concealed doublet, 1H, CHx), 4.62 (concealed 
doublet, 1H, CHy), 5.72 (s, 1H, CH), 7.39-7.67 (m, 
2H, Ar -H); MS m/z 461.2 (M+ +1) %; Anal. Calcd. 
For C19H20N6O4S2: C, 49.55; H, 4.38; N, 18.25%. 
Found C, 49.52; H, 4.35; N, 18.28%. 
2-(2,4-Dimethoxy-7-morpholinopyrido[2,3-d]pyr 
imidin-6-yl)-3-(5-methylthiazol-2-yl) thiazolidin-4-
one, 8b: Orange solid; m.p: 170-174oC; Yield: 70; IR 
(KBr, Vmax/cm-1): 3059 (C-H str., aromatic), 1475 
(C=C str., aromatic), 1473 (-C=C-C- str.,aromatic), 
1562 (C=N str.), 1178 (OCH3 str.), 1129 (C-O-C str., 
morpholine ring), 1360 (C-N str., morpholine ring), 
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1666 (C=O str., thiazolidine), 678 (C-S-C linkage, 
thiazolidine ring); 1H NMR (400 MHz, DMSO-d6, δ 
ppm): 2.30 (t, 4H, CH2, morpholine), 2.39 (t, 4H, 
CH2, morpholine), 3.60 (s, 3H, -OCH3), 3.71(s, 3H, -
OCH3), 2.57 (s, 3H,CH3), 6.98 (s, 1H, Ar-H), 3.84 ( d, 
1H, J = 5.2, CHx), 3.98 ( d, 1H, J = 5.2, CHy), 5.91 
(s, 1H, CH), 7.44 (s, 1H, Ar -H); MS m/z 475.3 (M+ 
+1) %; Anal. Calcd. For C20H22N6O4S2: C, 50.62; H, 
4.67; N, 17.71%. Found C, 50.65; H, 4.64; N, 
17.74%. 
2-(2, 4-Dimethoxy-7-morpholinopyrido[2,3-
d]pyrimidin-6-yl) -3- (5-methyl-1, 3, 4-thiadiazol-2-
yl) thiazolidin-4-one, 8c: Light-yellow solid; m.p: 
152-155oC; Yield: 60; IR (KBr, Vmax/cm-1): 3058 
(C-H str., aromatic), 1473 (C=C str., aromatic), 1570 
(C=N str.), 1454 (-C=C-C- str.,aromatic), 1176 
(OCH3 str.), 1137 (C-O-C str., morpholine ring), 1380 
(C-N str., morpholine ring), 1561 (C=C str., 
aromatic), 1684 (C=O str., thiazolidine), 678 (C-S-C 
linkage, thiazolidine ring); 1H NMR (400 MHz, 
DMSO-d6, δ ppm): 2.38 (t, 4H, CH2, morpholine), 
2.46 (t, 4H, CH2, morpholine), 3.68 (s, 3H, -OCH3), 
3.75 (s, 3H, -OCH3), 2.59 (s, 3H, CH3), 6.98 (s, 1H, 
Ar-H), 3.50 (d, 1H, J = 4.7 Hz, CHx), 4.67 (d, 1H, J = 
4.8Hz, CHy), 5.77 (s, 1H, CH); MS m/z 476.3 (M+ 
+1) %; Anal. Calcd. For C19H21N7O4S2: C, 47.99; H, 
4.45; N, 20.62%. Found C, 47.95; H, 4.41; N, 
20.58%. 
2-(2, 4-Dimethoxy-7-morpholinopyrido[2, 3-
d]pyrimidin-6-yl) -3- (5-mercapto-1, 3, 4-
thiadiazol-2-yl) thiazolidin-4-one, 8d: Light-yellow 
solid; m.p: 147-151ºC; Yield: 65; IR (KBr, Vmax/cm-
1): 3064 (C-H str., aromatic), 1480 (C=C str., 
aromatic), 1571 (C=N str.), 1190 (OCH3str.), 1472 (-
C=C-C- str.,aromatic), 1133 (C-O-C str., morpholine 
ring), 1376 (C-N str., morpholine ring), 1679 (C=O 
str., thiazolidine), 669 (C-S-C linkage, thiazolidine 
and ring) 2578 (-SH str.); 1H NMR (400 MHz, 
DMSO-d6, δ ppm): 2.35 (t, 4H, CH2 , morpholine), 
2.43 (t, 4H, CH2, morpholine), 3.66 (s, 3H, -OCH3), 
3.72 (s, 3H, -OCH3), 8.34 (s, 1H, SH), 6.98 (s, 1H, 
Ar-H), 3.64 ( d, 1H, J = 4.8Hz, CHx), 3.95 ( d, 1H, J 
= 4.6, CHy), 5.78 (s, 1H, CH); MS m/z 494.4 (M+ +1) 
%; Anal. Calcd. For C18H19N7O4S3: C, 43.80; H, 3.88; 
N, 19.86%. Found C, 43.84; H, 3.85; N, 19.83%. 
2-(2,4-Dimethoxy-7-morpholinopyrido[2,3-
d]pyrimidin-6-yl)-5-methyl-3- (thiazol-2-yl) 
thiazolidin-4-one, 9a: Light-orange solid; m.p: 183-
186ºC; Yield: 69; IR (KBr, Vmax/cm-1): 3058 (C-H 
str., aromatic), 1460 (C=C str., aromatic), 1565 (C=N 
str.), 1471 (-C=C-C- str.,aromatic),, 1176 (OCH3 str.), 
1133 (C-O-C str., morpholine ring), 1368 (C-N str., 
morpholine ring), 1676 (C=O str., thiazolidine), 1363 
(CH3 str.), 678 (C-S-C linkage, thiazolidin ring); 1H 
NMR (400 MHz, DMSO-d6, δ ppm): 2.37 (t, 4H, CH2 
, morpholine), 2.45 (t, 4H, CH2, morpholine), 3.66 (s, 
3H, -OCH3), 3.76 (s, 3H, -OCH3), 6.97 (s, 1H, Ar-H), 
3.6 (s, 3H, CH3), 4.4 (q, 1H, J = 7.4,-CH-CH3), 5.72 
(s, 1H, CH), 7.38-7.63 (m, 2H, Ar -H); MS m/z 475.2 
(M+ +1) %; Anal. Calcd. For C20H22N6O4S2: C, 50.62; 
H, 4.67; N, 17.71%. Found C, 50.65; H, 4.65; N, 
17.75%. 
 
2-(2,4-Dimethoxy-7-morpholinopyrido[2,3-d]pyr 
imidin-6-yl)-5-methyl-3-(5-methylthiazol-2-yl) 
thiazolidin-4-one, 9b: Light-orange solid; m.p: 179-
182ºC; Yield: 65; IR (KBr, Vmax/cm-1): 3056 (C-H 
str., aromatic), 1462 (C=C str., aromatic), 1575 (C=N 
str.), 1481 (-C=C-C- str.,aromatic), 1173 (OCH3 str.), 
1144 (C-O-C str., morpholine ring), 1374 (C-N str., 
morpholine ring), 1692 (C=O str., thiazolidine), 1354 
(CH3 str.), 680 (C-S-C linkage, thiazolidine ring); 1H 
NMR (400 MHz, DMSO-d6, δ ppm): 2.35 (t, 4H, CH2 
, morpholine), 2.44 (t, 4H, CH2, morpholine), 3.68 (s, 
3H, -OCH3), 3.74 (s, 3H, -OCH3), 2.31 (s, 3H, CH3), 
2.30 (s, 3H, CH3), 4.6 (q, 1H, J = 7.9 Hz, -CH-CH3), 
6.94 (s, 1H, CH-Ar), 5.93 (s, 1H, CH), 7.46 (s, 1H, Ar 
-H); MS m/z 489.4 (M+ +1) %; Anal. Calcd. For 
C21H24N6O4S2: C, 51.62; H, 4.95; N, 17.20%. Found 
C, 51.65; H, 4.92; N, 17.17%. 
 
2-(2, 4-Dimethoxy-7-morpholinopyrido[2,3-
d]pyrimidin-6-yl) -5-methyl-3- (5-methyl-1, 3, 4-
thiadiazol-2-yl) thiazolidin-4-one, 9c: Light-orange 
solid; m.p: 173-177ºC; IR (KBr, Vmax/cm-1): 3088 
(C-H str., aromatic), 1482 (C=C str., aromatic), 1559 
(C=N str.), 1476 (-C=C-C- str.,aromatic), 1184 
(OCH3 str.), 1135 (C-O-C str., morpholine ring), 1375 
(C-N str., morpholine ring), 1687 (C=O str., 
thiazolidine), 1349 (CH3 str.), 689 (C-S-C linkage, 
thiazolidine ring) ; 1H NMR (400 MHz, DMSO-d6, δ 
ppm): 2.38 (t, 4H, CH2 , morpholine), 2.46 (t, 4H, 
CH2, morpholine), 3.66 (s, 3H, -OCH3), 3.74 (s, 3H,-
OCH3), 2.57 (s, 3H, CH3), 1.40 (s, 1H, CH3), 6.97 (s, 
1H, Ar-H), 4.0 (q, 1H, J = 7.3 Hz, -CH-CH3), 5.75 (s, 
1H, CH); MS m/z 490.5 (M+ +1) ; Yield: 67%; Anal. 
Calcd. For C20H23N7O4S2: C, 49.07; H, 4.74; N, 
20.03%. Found C, 49.04; H, 4.71; N, 20.05%. 
 
2-(2, 4-Dimethoxy-7-morpholinopyrido [2, 3-d] 
pyrimidin-6-yl) -3-(5-mercapto-1, 3, 4-thiadiazol-2-
yl) -5-methylthiazolidin -4-one, 9d: Light-orange 
solid; m.p: 148-152ºC; Yield: 72; IR (KBr, Vmax/cm-1): 
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3078 (C-H str., aromatic), 1479 (C=C str., aromatic), 
1563 (C=N str.), 1471 (-C=C-C- str.,aromatic), 1186 
(OCH3 str.), 1142 (C-O-C str., morpholine ring), 1377 
(C-N str., morpholine ring), 1676 (C=O str., 
thiazolidine), 1361 (CH3 str.), 686 (C-S-C linkage, 
thiazolidine ring), 2550 (-SH. Str.) ; 1H NMR (400 
MHz, DMSO-d6, δ ppm): 2.38 (t, 4H, CH2, morpholine), 
2.42 (t, 4H, CH2, morpholine), 3.67 (s, 3H,-OCH3), 3.75 
(s, 3H, -OCH3), 1.43 (s, 3H, CH3), 4.7 (q, 1H, J = 7.6 
Hz, -CH-CH3), 5.93 (s, 1H, CH), 7.26 (s, 1H, Ar-H), 
8.37 (s, 1H, SH); MS m/z 508.6 (M+ +1) %; Anal. Calcd. 
For C19H21N7O4S3: C, 44.96; H, 4.17; N, 19.32%. Found 
C, 44.92; H, 4.15; N, 19.36%. 
 
Conclusion 
In conclusion, we have verified a feasible, extensive 
and very effective method for the synthesis of novel 
Schiff bases (7a-d), 2,3-disubstituted-4-thiazolidinone 
(8a-d) and 2,3-disubstituted-5-methyl-4-thiazolidinone 
(9a-d) derivatives was performed. The screening results 
revealed that all the compounds exhibited moderate to 
excellent activities against all the pathogenic strains. 
Among the newly synthesized compounds possessing 
electron donating or withdrawing group such as methyl, 
methoxy, sulfhydryl etc have been identified as the most 
potent antibacterial and antifungal agents. 
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